Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Seiler

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Urologic Oncology|August 3, 2020
Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on sizeKarl H Tully, Marco Moschini, Friedrich-Carl E von Rundstedt, et al.
European Urology|February 5, 2019
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder CancerJason A Efstathiou, Kent W Mouw, Ewan A Gibb, et al.
International Neurourology Journal|July 5, 2017
Targeting Moderate and Severe Male Stress Urinary Incontinence With Adjustable Male Slings and the Perineal Artificial Urinary Sphincter: Focus on Perioperative Complications and Device ExplantationsAlexander Kretschmer, Tanja Hüsch, Frauke Thomsen, et al.
European Urology Focus|October 28, 2017
Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European SurveyKees Hendricksen, Atiqullah Aziz, Perrine Bes, et al.
Molecular Cancer Therapeutics|August 28, 2020
Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder CancerYoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Urologic Oncology|April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Cancers|December 11, 2022
Oncological Outcomes for Patients Harboring Positive Surgical Margins Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Multicentric Study on Behalf of the YAU Urothelial GroupGautier Marcq, Luca Afferi, Yann Neuzillet, et al.
Urologia Internationalis|June 17, 2016
Complications and Short-Term Explantation Rate Following Artificial Urinary Sphincter Implantation: Results from a Large Middle European Multi-Institutional Case SeriesAlexander Kretschmer, Tanja Hüsch, Frauke Thomsen, et al.
European Urology Open Science|August 2, 2021
Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer GroupTom-Régis Dobé, Gianluigi Califano, Friedrich-Carl von Rundstedt, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Urologic Oncology|August 3, 2020
Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on sizeKarl H Tully, Marco Moschini, Friedrich-Carl E von Rundstedt, et al.
European Urology|February 5, 2019
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder CancerJason A Efstathiou, Kent W Mouw, Ewan A Gibb, et al.
International Neurourology Journal|July 5, 2017
Targeting Moderate and Severe Male Stress Urinary Incontinence With Adjustable Male Slings and the Perineal Artificial Urinary Sphincter: Focus on Perioperative Complications and Device ExplantationsAlexander Kretschmer, Tanja Hüsch, Frauke Thomsen, et al.
European Urology Focus|October 28, 2017
Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European SurveyKees Hendricksen, Atiqullah Aziz, Perrine Bes, et al.
Molecular Cancer Therapeutics|August 28, 2020
Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder CancerYoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Urologic Oncology|April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Cancers|December 11, 2022
Oncological Outcomes for Patients Harboring Positive Surgical Margins Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Multicentric Study on Behalf of the YAU Urothelial GroupGautier Marcq, Luca Afferi, Yann Neuzillet, et al.
Urologia Internationalis|June 17, 2016
Complications and Short-Term Explantation Rate Following Artificial Urinary Sphincter Implantation: Results from a Large Middle European Multi-Institutional Case SeriesAlexander Kretschmer, Tanja Hüsch, Frauke Thomsen, et al.
European Urology Open Science|August 2, 2021
Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer GroupTom-Régis Dobé, Gianluigi Califano, Friedrich-Carl von Rundstedt, et al.
Pageof 14